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Abstract
This study compared the possible protective effects of silymarin and melatonin against gentamicin (GEN)-induced nephrotoxicity
in rats. Rats were allocated to 6 groups: Group I, control group; Groups II and III, administered with silymarin or melatonin;
Group IV, injected with GEN; and Groups V and VI, administered with silymarin or melatonin, and then injected with GEN.
Compared with the rats in the control group, all rats injected with GEN significantly presented elevated levels of serum creatinine
and urea that was accompanied by an increase in relative kidney weight, increase in renal reactive oxygen species (ROS) and
malondialdehyde (MDA) levels, and reduction in renal glutathione (GSH) level and superoxide dismutase (SOD) activity. Silymarin
and melatonin pretreatment significantly lowered the elevated serum urea and creatinine concentration, kidney weight, and renal
ROS and MDA levels. In addition, silymarin and melatonin significantly enhanced renal GSH level and SOD activity. This study
indicates that silymarin and melatonin can attenuate renal injury in rats treated with GEN possibly by reducing the ROS level.
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Gentamicin (GEN), an antibiotic of the aminoglycoside group, is
still an important drug against life-threatening Gram-negative
infections. Despite the introduction of newer and less toxic anti-
biotics against Gram-negative microorganisms, its broad-
spectrum activity, rapid bactericidal action, postantibiotic effects,
chemical stability, low cost, and efficacy against germs insensitive
to other antibiotics have made it a first-line drug in a variety of clin-
ical situations.1,2 However, due to the risk of ototoxicity and
nephrotoxicity (serious side effects of GEN), its usefulness is lim-
ited. The major adverse effect of this drug is nephrotoxicity. GEN
nephrotoxicity accounts for 10% to 30% of acute renal failure that
markedly limits its clinical use.3-5 It has been suggested that GEN
nephrotoxicity may be related to its accumulation in renal proxi-
mal convoluted tubules, reaching a concentration of 5 to 50 times
higher than the plasma level in the tubular renal cell, leading to the
loss of brush border integrity.6 GEN nephrotoxicity is character-
ized functionally by markedly increased levels of serum creati-
nine, blood urea concentration, and significant decrease in
glomerular filtration and morphologically characterized by exten-
sive tubular epithelial cell vacuolation and desquamation, tubular
fibrosis, epithelial edema, glomerular hypertrophy, and severe
proximal renal tubular necrosis, linked to renal failure. The exact
mechanism of GEN nephrotoxicity is not well elucidated; how-
ever, several studies demonstrated that the nephrotoxic effect of
GEN can be mediated by increased generation of reactive oxygen
species (ROS) and reactive nitrogen species (RNS) and the
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reduction of efficiency of kidney antioxidant enzymes like super-
oxide dismutase (SOD), catalase (CAT), glutathione peroxidase
(GPX), and glutathione (GSH).7-9 Lipid peroxidation, protein
denaturation, DNA damage, and upregulation of caspase family
of proteases with subsequent apoptotic cell death and the increase
of monocyte/macrophages infiltration mediated by ROS are prox-
imal events in the cascade of GEN nephrotoxicity.10,11
N-Acetyl-5-methoxytryptamine or melatonin is the hormone
mainly produced by the pineal gland. It is known to be involved in
many physiological functions, including the modulation of circa-
dian rhythms, seasonal reproduction, and immune function.12,13
Melatonin also has a significant role in the improvement of cardi-
ovascular complication, sleeping disorders, migraine, and con-
vulsion therapy.14 In vivo and in vitro studies suggest that
melatonin might have a protective effect against free radicals
attack by acting as a radical scavenger; upregulating the expres-
sion of several intracellular antioxidative enzymes such as SOD,
CAT, glutathione reductase (GRd), and GPX; and stimulating the
synthesis of important endogenous antioxidant such as GSH.15,16
Silymarin is a flavonoid complex isolated from the seeds of
milk thistle (Silybum marianum), which has been used for the
treatment of liver diseases of varying origin. It is a mixture of
4 isomeric flavonoids: silibinin, isosilibinin, silydianin, and
silychristine. Among them silibinin is the major and most active
compound present in silymarin, which constitutes between 60%
and 70% of drug.17 Silymarin is widely used as a natural remedy
for the treatment of liver and gall bladder disorders such as hepa-
titis, cirrhosis, jaundice, and the protection of liver from injuries
caused by ischemia, radiation, alcohol abuse, iron overload, and
environmental toxins.18,19 It has also been reported that sily-
marin has beneficial effects in illnesses of different organs and
could be useful in treating diabetes and a wide range of cancers.
A number of studies have suggested that silymarin has antifibro-
tic, anti-lipid–peroxidative, anti-inflammatory, immunomodu-
lating, dose-dependent anti-apoptotic effects and acts as a
strong antioxidant and free radical scavenger.20
The present investigation was carried out to evaluate the
protective effects of silymarin and melatonin against GEN-
induced nephrotoxicity in Wistar albino rats.
Methods
Drugs and Chemicals
Gentamicin, silymarin, and melatonin were purchased from Sigma
(St Louis, MO).
Test Animals
The experimental protocols used in this study were approved by the
Ethics and Animal Care Committee of Zahedan University of Medical
Sciences and were performed in accordance with the National Institute
of Health Guidelines for the Care and Use of Laboratory Animals. Male
Wistar rats with an initial body weight of 230 to 260 g were used in this
study. The animals were kept in groups and housed in stainless steel cages
under standard environmental conditions at a temperature of 23+ 3C,
with 12-hour light/dark cycles. Standard commercial diet and water were
available ad libitum. The study was conducted in accordance with the
European Communities Council Directive in such a way to minimize the
number of animals used and their suffering.
Ethics
This study was performed according to the guidelines of the US
National Institute of Health (NIH Publication No. 85.23, revised
1985) guides for the care of laboratory animals.
Experimental Design
Thirty-six male Wistar albino rats were randomly divided into 6
groups each containing 6 rats.
Rats in Group I served as the control group and were consecutively
was injected intraperitoneally (ip) with physiological saline (1 mL/kg/
day) for 8 consecutive days. Rats in Groups II and III were administered
with silymarin (50 mg/kg/day, ip) or melatonin (15 mg/kg/day, ip) for 7
consecutive days. Rats in Group IV were injected with gentamicin sul-
fate (100 mg/kg/day, ip) for 8 consecutive days. Rats in Groups V and
VI were administered with silymarin (50 mg/kg/day, ip) or melatonin
(15 mg/kg/day, ip) for 7 consecutive days and then received injections
of gentamicin sulfate (100 mg/kg/day, ip) for 8 consecutive days.
Serum and Tissue Collection
After 8 days, the weight of animals was measured; then, they were
anesthetized by intraperitoneal injection of ketamine (30 mg/kg).
Blood samples (4-6 mL) were taken by cardiac puncture after which
the animals were sacrificed by cervical dislocation, kidneys quickly
removed, washed with ice-cold physiological saline, and the absolute
and relative (organ to body weight ratio) weights of the kidney mea-
sured for all rats. Kidneys were shock-frozen in liquid nitrogen and
were kept in 80C for lipid peroxidation and ROS assay.
Serum Biochemical Assays
To obtain serum, blood samples were centrifuged at 1500  g for 10
minutes atþ4C. Serum blood urea nitrogen (BUN) and creatinine lev-
els were determined using an autoanalyzer (BT-TARGA-3000 model).
Estimation of Lipid Peroxidation
Malondialdehyde (MDA) concentrations were measured in kidney tis-
sues as a marker of lipid peroxidation. Kidney tissues were homoge-
nized in ice-cold tamponade containing 150 mM KCl for the
determination of MDA. MDA, referred to as thiobarbituric acid reac-
tive substance (TBARS), was determined by the absorbance of 535 nm
wavelength, and the results were expressed as malondialdehyde
equivalents (nmol/mg protein).21
Assay of Superoxide Dismutase Activity
SOD activity was determined by using a commercially available SOD
assay kit (Sigma) according to the manufacturer’s instructions.
Dichlorofluorescein Assay for the Determination of
ROS Levels
ROS levels in kidney were determined by using the 20,70-dichloro-
fluorescein diacetate (DCF-DA) fluorescence method. The
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fluorescence intensity of DCF was measured by a fluorescence plate
reader using excitation at 485 nm and emission detection at 528 nm,
and the results were expressed as percentage change in fluorescence,
where the control group was taken as 100%.
Determination of GSH Level
Renal GSH level was determined according to a previously published
method22 with little modifications. The method is based on the reduction
of 5,5-dithiobis-2-nitrobenzoicacid by GSH to yield a yellow component.
The absorbance of this yellow component was measured at 412 nm and
compared with the standard curve to determine GSH concentration.
Statistical Analysis
The results are reported as mean+ SEM. The statistical analyses were
performed using one-way analysis of variance (ANOVA) by SPSS
software (version 20). Group differences were calculated by post hoc
analysis using Tukey test.
Results
Effects of Silymarin and Melatonin Treatments on Kidney
and Body Weight in GEN-Treated Rats
No deaths or remarkable signs of external toxicity were
observed in the groups of animals that were given GEN,
melatonin, or silymarin. Relative kidney weight significantly
increased (P < .01) in the GEN-treated group compared with
the control group, which could be ameliorated by the silymarin
or melatonin pretreatment (P < .01), whereas body weight was
not affected in any of the animal groups (Table 1).
Effects of Silymarin and Melatonin on Serum Creatinine
and Urea Levels in GEN-Treated Rats
Table 2 shows the serum urea and creatinine levels in control
and experimental groups of rats. In control animals, serum
creatinine and urea concentration were 0.63 + 0.01 and 20.4
+ 1.71 mg/dL, respectively. They significantly increased to
about 2-fold (P < .01 and P < .001, respectively) in the
GEN-treated group. Pretreatment with silymarin or melatonin
for 7 consecutive days prevented GEN-induced increase in
serum urea and creatinine levels significantly (P < .01 vs P <
.05; P < .05 vs P < .01, respectively).
Effects of Silymarin and Melatonin on Renal ROS and
MDA Levels in GEN-Treated Rats
A highly significant elevation was observed in MDA and ROS
levels in the kidneys of GEN-intoxicated rats when compared
with the control group (P < .001), while pretreatment of rats
with melatonin and silymarin significantly decreased renal
MDA and ROS levels (P < .01) when compared with the
GEN-treated group (Figures 1 and 2).
Effects of Silymarin and Melatonin Treatments on Renal
GSH Level and SOD Activity in GEN-Treated Rats
GSH level and SOD activity significantly decreased in the GEN-
treated group when compared with the control group (P < .001).
Pretreatment with silymarin and melatonin showed a highly sig-
nificant elevation in renal GSH level and SOD activity (P < .05
vs P < .01; P < .01 vs P < .001, respectively; Figures 3 and 4).
Discussion
Aminoglycoside antibiotics, and specially GEN, are well
known to cause serious nephrotoxicity and this toxic effect
limits their clinical usefulness. In this study, GEN was injected
consecutively at the dose of 100 mg/kg (ip) for 8 days. As
Table 1. Effects of GEN-Induced Alterations in the Body Weight Changes and Kidney Weights*.
Group
Items Control Silymarin Melatonin GEN GEN þ Silymarin GEN þ Melatonin
Body weight (g) 372.8 + 6.978 361.0+ 16.02 371.0 + 4.879 341.2+ 6.630 358.5 + 7.784 365.5 + 3.547
Kidney (g) 0.78 + 0.057 0.80+ 0.075b 0.79+ 0.05b 1.1+ 0.082a 0.81+ 0.053b 0.82 + 0.03b
Per body weight (%) 0.205 + 0.014 0.215+ 0.016d 0.213 + 0.014d 0.317+ 0.024c 0.220 + 0.015d 0.225 + 0.001d
Abbreviations: GEN, gentamicin; SEM, standard error of the mean; ANOVA, analysis of variance.
*The data are expressed as mean + SEM (n ¼ 6). The data were analyzed by one-way ANOVA followed by Tukey test.
aP < .05, cP < .001 compared to the control group.
bP < .05, dP < .01 compared to the GEN group.
Table 2. Effects of Melatonin and Silymarin on GEN-Induced Altera-
tions in the Serum Biochemical Parameters*.
Group Creatinine (mg/dL) BUN (mg/dL)
Control 0.63+ 0.01 20.4+ 1.71
Silymarin 0.76+ 0.08b 20 + 2.17e
Melatonin 0.65+ 0.07d 18.06+ 1.245c
GEN 1.155 + 0.12a 41.01+ 4.98c
GEN þ Silymarin 0.78+ 0.08b 24.84+ 2.82d
GEN þ Melatonin 0.69+ 0.049d 27.16+ 2.299b
Abbreviations: GEN, gentamicin; BUN, blood urea nitrogen; SEM, standard
error of the mean; ANOVA, analysis of variance.
*The data are expressed as mean+ SEM (n ¼ 6). The data were analyzed by
ANOVA followed by Tukey test.
aP < .01, cP < .001 compared to the control group. bP < .05, dP < .01, eP < .001
compared to the GEN group.
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expected, all rats injected with GEN alone presented reduced
renal function, which was correlated with elevated levels of
serum urea and creatinine. In the present study, it was shown
that the impairment of renal function was accompanied by an
increase in kidney weight, increase in renal ROS and MDA
levels, and reduction in renal GSH level and SOD activity. The
data obtained from the present work showed that pretreatment
of rats with melatonin (15 mg/kg/day, ip) for 7 days was able to
attenuate GEN-induced nephrotoxicity, and similar to melato-
nin, silymarin (50 mg/kg/day, ip) also could prevent nephro-
toxicity induced by GEN in rats.
The exact GEN nephrotoxicity mechanism is unknown, but
according to experimental data, oxygen free radicals are con-
sidered to be important mediators of GEN-mediated nephro-
toxicity.23 Some authors reported that GEN can stimulate
free radical formation by releasing iron from renal cortical
mitochondria and forming iron-GEN complexes by iron chela-
tion, which can be the initial step in GEN-induced ROS forma-
tion.24 This viewpoint is supported by an increase in serum urea
and creatinine levels, MDA level, an index of LPO, depletion
of kidney reduced GSH content, and low activity of antioxidant
enzymes such as SOD and CAT.25,26 Inactivation of these anti-
oxidant enzymes could be the result of increased production of
ROS, which could aggravate the oxidative damage. However,
the results of our study showed that pretreatment with melato-
nin (15 mg/kg/day, ip) induced a significant decrease in kidney
weight and serum urea and creatinine levels and improved the
GEN-induced suppression of GSH level, SOD activity, and ele-
vation of ROS and MDA levels in kidney tissue efficiently. It
has been well documented that melatonin (a pineal gland hor-
mone) has antioxidant properties in addition to its other biolo-
gical functions. Numerous reports have demonstrated that the
antioxidant effect of melatonin may result from its direct ability
to scavenge free radicals or its indirect antioxidant activity by
increasing the activity and expression of the antioxidative
enzymes.15,16
Melatonin is an effective scavenger of ROS and RNS
including singlet oxygen (1O2), superoxide radical (O2
),
hydroxyl radical (OH), hydrogen peroxide (H2O2), nitric
oxide (NO), and peroxynitrite anion (ONOO). In addition,
melatonin can inhibit the catalytic activity of nitric oxide
synthase (NOS) and expression of inducible nitric oxide
synthase (iNOS) at the transcriptional level that reduces the
amount of NO produced.27 Besides direct scavenger activity,
melatonin can stimulate gene expression and activities of sev-
eral antioxidative enzymes including GRd, GPX, CAT, and
SOD, and this indirect antioxidant activity of melatonin is
related to its interaction with either membrane or nuclear recep-
tors. These antioxidative enzymes can metabolize free radicals
Figure 1. Levels of lipid peroxidation in the kidneys of control and
experimental animals.
The data are expressed as mean + SEM (n ¼ 6).
aP < .001 compared to the control group. bP < .01, cP < .001 compared
to the GEN group.
Figure 4. Levels of glutathione (GSH) in the kidneys of control and
experimental animals.
The data are expressed as mean + SEM (n ¼ 6).
aP < .001 compared to the control group. bP < .05, cP < .01, eP < .001
compared to the GEN group.
Figure 3. Levels of superoxide dismutase (SOD) in the kidneys of
control and experimental animals.
The data are expressed as mean + SEM (n ¼ 6).
aP < .001 compared to the control group. bP < .01, cP < .001 compared
to the GEN group.
Figure 2. Levels of reactive oxygen species (ROS;% of control) in the
kidneys of control and experimental animals.
The data are expressed as mean + SEM (n ¼ 6).
aP < .001 compared to the control group. bP < .01, cP < .001 compared
to the GEN group.
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to less reactive species and thereby decrease the formation of
highly toxic by-products. For example, SOD can reduce free
radical–mediated cellular damage as a result of producing
H2O2 by dismutasing O2
; CAT converts H2O2 to water and
oxygen; GPX, by oxidizing GSH to glutathione disulfide
(GSSG) can metabolize peroxides such as H2O2 to water, and
then GRd reduces GSSG to GSH. It has been shown that mel-
atonin by stimulating its rate-limiting enzyme, g-glutamylcys-
teine synthase, increases the synthesis of GSH. Experimental
studies show that administration of melatonin for long periods
increases mitochondrial number in cells. Furthermore, it has
been shown that there are mitochondrial binding sites for
melatonin. Additionally, treatment of mitochondria with mela-
tonin improved the efficiency of the oxidative phosphorylation
metabolic pathway and consequently reduced the leakage of
electrons and formation of free radicals. Also, melatonin upre-
gulates the production of ATP, which is vital for cellular func-
tions including the repair of molecular damage created by ROS
and RNS.28-31 Previous studies indicate that melatonin can pro-
tect kidneys against pathological conditions. It has been shown
that melatonin is able to prevent renal functional impairment
induced by oxygen free radicals resulting from cyclosporine
in rats without any alteration in cyclosporine plasma levels.32
It has also reduced renal oxidative damage induced by alumi-
num, lead, ochratoxin, mechlorethamine, spinal cord and ther-
mal injury and has been able to improve early glomerulopathy
mediated by oxidative stress in diabetic rats’ kidneys.33-40 In
another study, it has been shown that melatonin had protective
effect against hamster kidney model of estradiol-induced DNA
damage.41 In our previous study, we showed melatonin is able
to enhance the beneficial effects of atorvastatin against GEN-
induced nephrotoxicity.42 Also, there are other studies about
the protective effects of melatonin in GEN-induced nephro-
toxicity, and our results are entirely consistent with the other
studies.27,43-46 Our results also showed that pretreatment with
silymarin at a dose higher than melatonin (50 mg/kg/day, ip)
had protective effects against nephrotoxicity induced by GEN
in rats. Silymarin was significantly able to decrease kidney
weight and serum urea and creatinine levels and efficiently
improved the suppression of GSH level and SOD activity
and elevated levels of ROS and MDA induced by GEN in kid-
ney tissue. According to experimental and human studies,
silymarin has good antioxidant activity, and this property
may be due to the inhibition of the initiation step in auto-
oxidation by silymarin and its free radical scavenger activ-
ity.47,48 It has probable antagonizing effects against the
depletion of endogenous antioxidant defenses, such as those
mediated by SOD or the GSH system through free radical
load decrease, upregulation of GSH levels, and stimulation
of SOD activity.49
A number of studies have demonstrated that silymarin has
a regulatory action on cellular membrane permeability and
improves the membranes’ stability against xenobiotic-induced
damage. Furthermore, silymarin has nuclear expression regula-
tory capacity. It is appeared that silymarin stimulates RNA poly-
merase I and the transcription of rRNA by which it increases
the synthesis of ribosomal RNA (rRNA) species. The loss or
functional impairment of transporters and enzymes occur in
many pathological conditions and the stimulation of protein
synthesis is an important step for counteracting it.17,31 It has
also been shown that silymarin by effective induction of anti-
oxidant related genes, including the transcription factor NF-
E2-related factor-2 (Nrf2), can act as a potent cytoprotective
effector. The transcription factor Nrf2 can regulate the
expression of a variety of cytoprotective and phase II detoxi-
fying enzymes, such as glutathione S-transferase (GST) and
SOD.50 Also it has been reported that silymarin and its biolo-
gically active component, silybin, are powerful iron chelators
that reduce serum iron and ferritin and thus they are able to
inhibit Fe2þ salts catalyzing linoleic acid oxidation. These
data suggest that iron chelating activity can be one of the pro-
tective mechanisms of silymarin against GEN-induced oxida-
tive damage.51 Maybe this property of silymarin inhibits the
formation of iron-GEN complex and its renal accumulation.
Renoprotective effects of silymarin have been reported in sev-
eral studies. It has been shown silymarin is able to increase
antioxidant enzymes and a number of protection mechanisms
against free radical damage in alloxan-induced pancreatic dam-
age in rats and also antagonize cisplatin- and ifosfamide-induced
renal toxicity without reducing their antitumor efficacy. It has
also been reported that treatment with silymarin or vitamin E
in GEN-treated dogs improved alteration in serum creatinine
and MDA concentrations, which may be due to its antioxidant
activity.52-54
From the results of the present study, it could be inferred
that the pretreatment of rats with melatonin and silymarin inhi-
bits GEN-induced nephrotoxicity, and it seems that melatonin
can induce this effect at a dose lesser than silymarin. Adminis-
tration of silymarin and melatonin prior to GEN exposure
resulted in a marked decline in kidney weight and serum urea
and creatinine concentrations, renal ROS and MDA levels, and
also significant elevation in renal GSH level and SOD activity.
These results suggest that the protective effect of silymarin and
melatonin may be caused by their antioxidant properties.
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